JPMorgan analyst Brian Essex raised the firm’s price target on Cellebrite (CLBT) to $24 from $23 and keeps an Overweight rating on the shares. The company reported solid Q3 results with “multiple levers” to drive growth in 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite DI: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
- Cellebrite Reports Strong Q3 2025 Financial Results
- Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise
- Cellebrite Reports Strong Q3 2025 Financial Results with 18% Revenue Growth